{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:42:38Z","timestamp":1702600958144},"reference-count":57,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary brain tumors underwent reclassification in the 2021 World Health Organization update, relying on molecular findings (especially isocitrate dehydrogenase mutations and chromosomal changes in 1p, 19q, gain of chromosome 7 and loss of chromosome 10). Newer entities have also been described including histone 3 mutant midline gliomas. These updated pathologic classifications improve prognostication and reliable diagnosis, but may confuse interpretation of prior clinical trials and require reclassification of patients diagnosed in the past. For patients over seventy, multiple studies have now confirmed the utility of shorter courses of radiation, and the risk of post-operative delirium. Ongoing studies are comparing proton to photon radiation. Long term follow up of prior clinical trials have confirmed the roles and length of chemotherapy (mainly temozolomide) in different tumors, as well as the wearable novottf device. New oral isocitrate dehydrogenase inhibitors have also shown efficacy in clinical trials.<\/jats:p>","DOI":"10.1055\/s-0043-1776764","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T23:36:40Z","timestamp":1702597000000},"page":"889-896","source":"Crossref","is-referenced-by-count":0,"title":["Neuro-oncology Treatment Strategies for Primary Glial Tumors"],"prefix":"10.1055","volume":"43","author":[{"given":"Fernando","family":"Santos-Pinheiro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome J.","family":"Graber","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, University of Washington, Alvord Brain Tumor Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"S 05","key":"ref1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Q T Ostrom","year":"2019","journal-title":"Neuro-oncol"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"D J Brat","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"17","key":"ref3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"C Houillier","year":"2010","journal-title":"Neurology"},{"issue":"25","key":"ref4","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"M Sanson","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"L Dang","year":"2009","journal-title":"Nature"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"H Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"C Lu","year":"2012","journal-title":"Nature"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ccell.2018.05.010","article-title":"ROS promotes cancer cell survival through calcium signaling","volume":"33","author":"C R Reczek","year":"2018","journal-title":"Cancer Cell"},{"issue":"19","key":"ref9","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","article-title":"Mutant IDH1 and seizures in patients with glioma","volume":"88","author":"H Chen","year":"2017","journal-title":"Neurology"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00005072-199311000-00008","article-title":"Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index","volume":"52","author":"S W Coons","year":"1993","journal-title":"J Neuropathol Exp Neurol"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/1097-0142(19800101)45:1<112::AID-CNCR2820450121>3.0.CO;2-9","article-title":"Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature","volume":"45","author":"B Pasquier","year":"1980","journal-title":"Cancer"},{"issue":"21","key":"ref12","doi-asserted-by":"crossref","first-page":"e2483","DOI":"10.1212\/WNL.0000000000007529","article-title":"Leptomeningeal metastases in glioma: the Memorial Sloan Kettering Cancer Center experience","volume":"92","author":"B M Andersen","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"e0188419","DOI":"10.1371\/journal.pone.0188419","article-title":"Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases","volume":"12","author":"M Zetterling","year":"2017","journal-title":"PLoS One"},{"issue":"20","key":"ref14","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-17-0560","article-title":"T2-FLAIR mismatch, an imaging biomarker for IDH and 1p\/19q status in lower-grade gliomas: a TCGA\/TCIA Project","volume":"23","author":"S H Patel","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"e1582","DOI":"10.1212\/WNL.0000000000010324","article-title":"T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: variability and evolution","volume":"95","author":"P Throckmorton","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/neuonc\/noy113","article-title":"2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data","volume":"20","author":"C H Suh","year":"2018","journal-title":"Neuro-oncol"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2007.13.9337","article-title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","volume":"26","author":"J S Smith","year":"2008","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","article-title":"Surgical resection versus watchful waiting in low-grade gliomas","volume":"28","author":"A S Jakola","year":"2017","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.002","article-title":"Evidence-based recommendations on categories for extent of resection in diffuse glioma","volume":"149","author":"P Karschnia","year":"2021","journal-title":"Eur J Cancer"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3171\/2019.2.JNS183408","article-title":"(2020). Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome","volume":"132","author":"M. Rossi","journal-title":"Journal of Neurosurgery JNS"},{"issue":"21","key":"ref21","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1212\/WNL.0b013e3181e04264","article-title":"Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities","volume":"74","author":"J Pallud","year":"2010","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"M J van den Bent","year":"2005","journal-title":"Lancet"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2002.09.126","article-title":"Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group\/Radiation Therapy Oncology Group\/Eastern Cooperative Oncology Group study","volume":"20","author":"E Shaw","year":"2002","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11060-017-2558-x","article-title":"NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients","volume":"137","author":"A N Ali","year":"2018","journal-title":"J Neurooncol"},{"issue":"25","key":"ref25","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","article-title":"Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802","volume":"30","author":"E G Shaw","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"ref26","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"J C Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"M J van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"G Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"ref29","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint Final Report of EORTC 26951 and RTOG 9402: Phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors","volume":"40","author":"A B Lassman","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","article-title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study","volume":"390","author":"M J van den Bent","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"ref31","first-page":"1529","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"W Wick","year":"2016","journal-title":"Neuro-oncol"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/neuonc\/noaa168","article-title":"CODEL: phase III study of RT, RT\u2009+ TMZ, or TMZ for newly diagnosed 1p\/19q codeleted oligodendroglioma. Analysis from the initial study design","volume":"23","author":"K A Jaeckle","year":"2021","journal-title":"Neuro-oncol"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO Guideline","volume":"40","author":"N A Mohile","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"ref34","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1212\/01.wnl.0000277271.47601.a1","article-title":"Outcome in adult low-grade glioma: the impact of prognostic factors and treatment","volume":"69","author":"D Schiff","year":"2007","journal-title":"Neurology"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2014.10.FOCUS12367","article-title":"Survival and low-grade glioma: the emergence of genetic information","volume":"38","author":"E B Claus","year":"2015","journal-title":"Neurosurg Focus"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10143-016-0709-8","article-title":"Current and future strategies for treatment of glioma","volume":"40","author":"N A Bush","year":"2017","journal-title":"Neurosurg Rev"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"102124","DOI":"10.1016\/j.ctrv.2020.102124","article-title":"A basic review on systemic treatment options in WHO grade II-III gliomas","volume":"92","author":"M J Mair","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"100396","DOI":"10.1016\/j.lanepe.2022.100396","article-title":"Evaluating the lack of impact of the e-health application Oncokompas on outcomes in incurably ill cancer patients","volume":"18","author":"L Dirven","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ncl.2022.10.005","article-title":"Neuro-oncology in women: clinical considerations","volume":"41","author":"L Singer","year":"2023","journal-title":"Neurol Clin"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"e2213070","DOI":"10.1001\/jamanetworkopen.2022.13070","article-title":"Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines","volume":"5","author":"T A Yap","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jon.12687","article-title":"Clinical imaging for diagnostic challenges in the management of gliomas: a review","volume":"30","author":"A V Bonm","year":"2020","journal-title":"J Neuroimaging"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11060-012-0824-5","article-title":"Measuring clinical outcomes in neuro-oncology. A battery to evaluate low-grade gliomas (LGG)","volume":"108","author":"C Papagno","year":"2012","journal-title":"J Neurooncol"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"I K Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11060-022-04024-5","article-title":"Adult diffuse midline gliomas H3\u2009K27-altered: review of a redefined entity","volume":"158","author":"C A L\u00f3pez-P\u00e9rez","year":"2022","journal-title":"J Neurooncol"},{"issue":"23","key":"ref45","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"R Stupp","year":"2017","journal-title":"JAMA"},{"issue":"03","key":"ref46","first-page":"CD013316","article-title":"Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide","volume":"3","author":"A McAleenan","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11060-021-03886-5","article-title":"Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825","volume":"155","author":"N Patil","year":"2021","journal-title":"J Neurooncol"},{"issue":"01","key":"ref48","first-page":"vdac030","article-title":"Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas","volume":"4","author":"K Lam","year":"2022","journal-title":"Neurooncol Adv"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"U Herrlinger","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3174\/ajnr.A6843","article-title":"Centrally reduced diffusion sign for differentiation between treatment-related lesions and glioma progression: a validation study","volume":"41","author":"P Alcaide-Leon","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"issue":"03","key":"ref51","first-page":"CD013261","article-title":"Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis","volume":"3","author":"C Hanna","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/neuros\/nyx606","article-title":"Postoperative delirium in glioblastoma patients: risk factors and prognostic implications","volume":"83","author":"P M Flanigan","year":"2018","journal-title":"Neurosurgery"},{"key":"ref53","first-page":"1","article-title":"Efficacy and safety of bevacizumab for treating glioblastoma: a systemic review and meta-analysis of phase II and III randomized controlled trials","volume":"2","author":"X Xie","year":"2023","journal-title":"Cancer Invest"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11060-012-0855-y","article-title":"Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis","volume":"108","author":"T E Gofton","year":"2012","journal-title":"J Neurooncol"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"836","DOI":"10.21037\/apm-2019-pcno-12","article-title":"Palliative care in neuro-oncology","volume":"10","author":"J J Graber","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-022-03971-3","article-title":"Quality indicators in neuro-oncology: review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey","volume":"157","author":"D Vanhauwaert","year":"2022","journal-title":"J Neurooncol"},{"issue":"03","key":"ref57","first-page":"e309","article-title":"Disputes and debates: comment on Lin et al. \u201cGeographic variation in neurologist density and neurologic care in the United States\u201d","volume":"96","author":"C C Lin","year":"2021","journal-title":"Neurology"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1776764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T23:40:39Z","timestamp":1702597239000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1776764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":57,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2023,12,14]]},"published-print":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1776764","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}